Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
St. Jude Children's Research Hospital
mi
from
Memphis, TN
Click here to add this to my saved trials
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
Children's Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated:  11/17/2015
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma
Status: Enrolling
Updated: 11/17/2015
Children's Hospital of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Cedars Sinai Medical Center The Pituitary Center (3)
mi
from
Los Angeles, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Cedars Sinai Medical Center The Pituitary Center (3)
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Cedars Sinai Medical Center Cedars Sinai 4
mi
from
Los Angeles, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Cedars Sinai Medical Center Cedars Sinai 4
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Stanford University Medical Center SC
mi
from
Stanford, CA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Stanford University Medical Center SC
mi
from
Stanford, CA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5)
mi
from
Boston, MA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Dana Farber Cancer Institute Deptof DanaFarberCancerInst(5)
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Mount Sinai School of Medicine Study Coordinator
mi
from
New York, NY
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Mount Sinai School of Medicine Study Coordinator
mi
from
New York, NY
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Swedish Medical Center Dept.ofSwedishMedicalCtr.(2)
mi
from
Seattle, WA
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Swedish Medical Center Dept.ofSwedishMedicalCtr.(2)
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated:  11/18/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
An Open Label, Multicenter, Single Arm Study of Pasireotide LAR in Patients With Rate Tumors of Neuroendocrine Origin
Status: Enrolling
Updated: 11/18/2015
Novartis Investigative Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Childrens Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Lucile Packard Children's Hospital Stanford University
mi
from
Palo Alto, CA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Children's Hospital Colorado
mi
from
Aurora, CO
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
University of Chicago Comer Children's Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
C S Mott Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Cook Children's Medical Center
mi
from
Fort Worth, TX
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Cook Children's Medical Center
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Seattle Children's Hospital
mi
from
Seattle, WA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
UCSF Medical Center at Parnassus
mi
from
San Francisco, CA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Boston Children's Hospital
mi
from
Boston, MA
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Boston Children's Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated:  11/23/2015
Hospital for Sick Children
mi
from
Toronto,
Vorinostat and Isotretinoin in Treating Patients With High-Risk Refractory or Recurrent Neuroblastoma
Phase I Study of Vorinostat in Combination With 13-Cis-retinoic Acid in Patients With Refractory/Recurrent Neuroblastoma
Status: Enrolling
Updated: 11/23/2015
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
University of Iowa
mi
from
Iowa City, IA
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Johns Hopkins University
mi
from
Baltimore, MD
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
CS Motts Children's Hospital
mi
from
Ann Arbor, MI
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
CS Motts Children's Hospital
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Hospital - Weill Cornell Medical Center
mi
from
New York, NY
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Hospital - Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Medical University of South Carolina
mi
from
Charleston, SC
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Children's Hospital of LA
mi
from
Los Angeles, CA
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Children's Hospital of LA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
UCSF Pediatric Hematology/Oncology
mi
from
San Francisco, CA
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
UCSF Pediatric Hematology/Oncology
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Childrens Memorial/Northwestern University
mi
from
Chicago, IL
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Childrens Memorial/Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Comer's Childrens Hospital/University of Chicago
mi
from
Chicago, IL
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Comer's Childrens Hospital/University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Children's Hospital/Dana Farber Cancer Institute
mi
from
Boston, MA
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Children's Hospital/Dana Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Memorial Sloan-Kettering
mi
from
New York, NY
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Memorial Sloan-Kettering
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Cincinnati Children's Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Children's Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Cook Children's Healthcare System
mi
from
Fort Worth, TX
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Cook Children's Healthcare System
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Texas Childrens Hospital Cancer Center
mi
from
Houston, TX
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Texas Childrens Hospital Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
University of Wisconsin Medical Center
mi
from
Madison, WI
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
University of Wisconsin Medical Center
mi
from
Madison, WI
Click here to add this to my saved trials
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated:  11/24/2015
Hospital for Sick Children
mi
from
Toronto,
Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma
A Phase 2b Study Evaluating the Efficacy and Safety of Ultratrace™ Iobenguane I 131 Among Patients With Relapsed/Refractory High-Risk Neuroblastoma
Status: Enrolling
Updated: 11/24/2015
Hospital for Sick Children
mi
from
Toronto,
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
University of Arizona Medical Center
mi
from
Tucson, AZ
Click here to add this to my saved trials
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated:  11/24/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Status: Enrolling
Updated: 11/24/2015
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials